












1154Pharmacologic Expansion of Donor-Derived, Naturally
Occurring CD41Foxp31 Regulatory T Cells Reduces
Acute Graft-versus-Host Disease Lethality Without
Abrogating the Graft-versus-Leukemia Effect
in Murine Models
Omar Duramad,1 Amy Laysang,1 Jun Li,1 Yasuyuki Ishii,2 Reiko Namikawa1Adoptive transfer of regulatory T cells (Tregs) prevents graft-versus-host disease (GVHD) in mouse models,
indicating a pivotal role for Tregs in controlling GVHD. The present study demonstrates the efficacy of Tregs
pharmacologically induced in vivo in GVHD prevention. A single i.v. administration of a liposomal formulation
of a-galactosylceramide (RGI-2001) at the time of allogeneic bone marrow transplantation with spleen cells
significantly prolonged the survival of mice experiencing lethal acute GVHD. RGI-2001 expanded donor-
derived CD41Foxp31 Tregs in the spleen, lymph nodes, and bone marrow in a dose-dependent manner.
On day 15 posttransplantation, the spleens of mice treated with RGI-2001 (1 mg/kg) contained 5-fold higher
percentages or 10-fold higher numbers of CD41Foxp31 Tregs compared with the spleens of untreatedmice.
Host-specific immunosuppression was introduced in treated mice, whereas the responsiveness to third-
party alloantigens and leukemia cells was maintained. Using Foxp3:GFP reporter mice as donors, it was
clearly shown that RGI-2001 expanded the pre-existing naturally occurring Tregs (nTregs) in donor spleen
cells. Finally, RGI-2001 synergized with a subtherapeutic dose of rapamycin in nTreg expansion and further
prolonged survival. Our results provide the first demonstration of the efficacy of nTregs pharmacologically
expanded in vivo in preventing acute GVHDwithout abrogation of the beneficial graft-versus-leukemia effect.
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The CD41CD251Foxp31 regulatory T cells
(Tregs) are considered the key players in maintaining
peripheral tolerance [1,2]. Animal studies have
demonstrated that these cells prevent or ameliorate
various T cell–mediated diseases, including auto-
immune diseases and transplantation, by restoring
immune tolerance to self-antigens as well as to alloanti-
gens [3]. Studies in both humans and mice have de-
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ment of Treg-based therapeutic modalities has been
hampered, however, due in part to the paucity of this
cell population. Although conditions to expand Tregs
in vitro have been established [5,6], translating Tregs
into the clinical setting has been hindered by technical
challenges, including isolation, large-scale expansion,
and regulatory requirements [7]. The discovery of mol-
ecules that can efficiently expand functional Tregs in
vivowould contribute to the development of novel ther-
apies for the treatment of GVHD as well as other im-
mune disorders. Various strategies to activate and
expand Tregs in situ are emerging [8].
KRN7000 is a synthetic derivative of a-galactosyl-
ceramide, a glycolipid originally discovered from a
marine sponge [9]. It serves as a ligand for the
CD1d molecule, expressed on antigen-presenting cells
[10,11]. The CD1d molecule is a nonpolymorphic,
major histocompatibility complex (MHC) class I–like
antigen-presenting molecule with an antigen-binding
groove adapted for the presentation of lipid antigens
[12,13]. When KRN7000 is presented by CD1d
molecules expressed on various cell types, including
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recognized by an invariant T cell receptor (TCR)
expressed on invariant natural killer T (iNKT) cells,
and activates iNKT cells in a CD1d-restricted manner
[14]. CD1d-restricted iNKT cell activation results in
a rapid release of large amounts of both Th1 and
Th2 cytokines, a unique property that distinguishes
iNKT cells from conventional T cells and suggests
their important immunoregulatory roles in both in-
nate and adaptive immunity.
Whereas KRN7000, given in an aqueous form,
has been shown to act as an immunostimulating agent,
a liposomal formulation of KRN7000 was found to
induce antigen-specific immune suppression or toler-
ance [15,16]. Previous studies have suggested that
differential cell targeting by liposomal KRN7000
results in different immunomodulatory responses. In
brief, aqueous KRN7000 is presented mainly by
DCs, thereby stimulating iNKT cells in the presence
of interleukin (IL)-12 secreted by DCs. In contrast,
the interaction of iNKT cells with KRN7000
presented on B cells induces production of IL-10
from both iNKT cells and B cells, resulting in
expansion of tolerogenicDCs [15], which subsequently
induces the generation of antigen-specific
Foxp31CD41CD25high Tregs in the presence of
a model antigen, ovalbumin [15,16]. It is conceivable
that the lipid composition of liposomes enhances the
uptake of the liposomal KRN7000 by B cells, thereby
skewing immune responses toward the tolerogenic
direction.
In the present study, we investigated whether a li-
posomal KRN7000 (RGI-2001) can induce
alloantigen-specific tolerance throughTreg induction.
Specifically, we evaluated the efficacy of RGI-2001 in
a murine acute GVHD model, and found that a single
injection of RGI-2001 significantly prolonged the sur-
vival of mice. Enhanced expansion of donor-derived
CD41Foxp31Tregs was seen to be the key underlying
mechanism. Host-alloantigen specific immune sup-
pression was induced early after bone marrow trans-
plantation (BMT), but responses to third-party
alloantigens or leukemia cells were not abrogated.
Our results suggest the possibility of developing novel
therapies for the prevention of GVHD by pharmaco-
logically exploiting intrinsic immunoregulatory path-
ways for induction and maintenance of tolerance.MATERIALS AND METHODS
Mice
The 8- to 10-week-old female BALB/c (H-2d),
C57BL/6J (H-2b), FVB (H-2q), C3H (H-2k), and
Foxp3:GFP reportermice [17] (C57BL/6 background)
were obtained from Jackson Laboratory (Sacramento,
CA, or Bar Harbor, ME). All experiments wereapproved by an internal and external Committee on
the Use and Care of Laboratory Animals.
Treatments
RGI-2001 (KRN7000 embedded in a liposomal
bilayer) and the control liposomal formulation were
prepared at REGiMMUNE. The doses were ex-
pressed based on the dose of KRN7000 and calculated
assuming a mouse body weight of 20 g. RGI-2001 and
the control formulation were diluted in 1 Hank’s
buffered saline solution for i.v. injection. Rapamycin
(RAPA) from Streptomyces hygroscopicus (R0395;
Sigma-Aldrich, St Louis, MO) was dissolved in a 1%
carboxymethylcellulose sodium salt solution (C5013;
Sigma-Aldrich) and stored in the dark at 4C. RAPA
was administered intraperitoneally (i.p.).
Antibodies
The following fluorochrome-conjugated anti-
bodies were used for flow cytometry analysis: CD4,
CD25, TCR-b, H-2kd, and H-2kb (all from BD Phar-
mingen, San Diego, CA) and anti-Foxp3 antibody
(eBioscience, San Diego, CA). iNKT cells were de-
tected using a KRN7000-loaded CD1d:tetramer
(Proimmune, Oxford, UK) as described previously
[18]. Staining was performed in the presence of puri-
fied anti-CD16/32 (BD Pharmingen) at saturation to
block unspecific staining.
Flow Cytometry
Cell samples were analyzed with a Calibur flow cy-
tometer (BD Biosciences, San Jose, CA), and acquired
data were analyzed using FloJo software (Treestar,
Ashland, OR). The percentage of iNKT cells was indi-
cated as the CD1d tetramer1 cells in the total TCR-
b1 cells, and that of CD41Foxp31Tregs was indicated
as the Foxp31 population among the total CD41 cells.
Single-cell suspensions from spleens of Foxp3:GFP
reporter mice were sorted on a FACSAria cell sorter
(BD Biosciences) for the Foxp3:GFP- population.
Cytokine Measurements
Serum samples were analyzed for cytokines using
RodentMAP v 2.0 (Rules-Based Medicine, Austin,
TX).
GVHD Models and Cell Isolation
Lethally irradiated Balb/c mice were used as recip-
ients, and C57BL/6, FVB, or Foxp3:GFP reporter
mice were used as donors. Recipient mice were irradi-
ated with 800 cGy at Stanford Research Institute using
a Pantak X-ray energy source on the day of transplan-
tation. Dynal Mouse Pan T (Thy1.2) beads (Invitro-
gen, Carlsbad, CA) were used to remove T cells from
the donor bone marrow cells (BMCs). Depletion of
T cells was verified by fluorescence-activated cell
1156 Biol Blood Marrow Transplant 17:1154-1168, 2011O. Duramad et al.sorter (FACS) analysis using TCR-b staining, which
was routinely .90% for C57BL/6 and .97% for
Foxp3:GFP reporter mice. A total of 5  106 T cell–
depleted (TCD) BMCs were infused via a tail vein
with 2.5  106 donor whole spleen cells (WSCs).
RGI-2001 was administered i.v. via another tail vein
approximately 30 minutes after donor cell infusion.
The day of BMT was considered day 0. Mice were
maintained under sterile conditions with autoclaved
cages, bedding, and water supplemented with Poly-
mixin B and were observed daily for survival.
Mixed Lymphocyte Reaction
WSCs isolated from recipient mice were used as
responder cells. Allogeneic WSCs, treated with mito-
mycin C (50 mg/mL; Sigma-Aldrich) and depleted for
T cells as described above, were used as stimulator
cells. Cultures were evaluated in triplicate in 96-well
round-bottomed plates in a total volume of 200 mL.
Cells were cultured in RPMI 1640 medium (Invitro-
gen) containing 10% fetal bovine serum (Invitrogen),
10 mM Hepes (pH 7.2; Invitrogen), 1 L-glutamine
(2 mM), 1 Na pyruvate (1 mM) (Invitrogen), 1
penicillin-streptomycin (Invitrogen), and 0.5 antibi-
otic/mycotic (Invitrogen). The optimal coculture con-
dition was established at a 10:1 responder:stimulator
ratio. Cell proliferation was analyzed on day 3 or day
4 by a colorimetric assay using alamarBlue (Serotec,
Raleigh, NC).
Tumor Model
The in vivo adapted A20-luc/yfp cell line (Balb/c
origin), transduced with the yellow fluorescent protein
(YFP)/luciferase genes [19], was a generous gift from
Dr. Robert Negrin, Stanford University Medical
Center. A total of 5  104 A20-luc/yfp cells were ad-
ministered i.v. into irradiated Balb/c recipients ap-
proximately 60 minutes before the infusion of TCD
BMCs and WSCs. Mice were examined daily. The
presence of tumor cells was evaluated macroscopically
at the time of necropsy and analyzed by FACS based on
the YFP signal detectable by the FL1 laser [20].
Statistical Analysis
Statistical data were analyzed using the Student’s
t test (unpaired, two-tailed). GVHD Kaplan-Meier
survival curves were analyzed using the log-rank test.
A P value\.05 was considered statistically significant.RESULTS
RGI-2001 Induces Cytokine Production and
iNKT Cell Expansion In Vivo
The activities of RGI-2001 in cytokine production
and iNKT cell expansion were investigated in Balb/cand C57BL/6 mice. Administration of varying doses
of RGI-2001 induced elevated serum levels of IL-2,
IL-4, and interferon (IFN)-g in a dose-dependent
manner (Figure S1A-C). The peak levels of IL-2 and
IL-4 were measured at 2 hours postinjection, and
that of IFN-g was seen at 16-20 hours postinjection.
RGI-2001 induced expansion of iNKT cells in
a dose-dependent manner, reaching a maximum 4- to
6-fold expansion (Figure S1D). These observations
are consistent with findings reported previously with
an aqueous form of KRN7000 [21]. In general, induc-
tion of cytokines and iNKT cells was observed at doses
of$ 0.01 mg/kg. Treatment with the control formula-
tion at a lipid dose equivalent to 10 mg/kg of RGI-2001
did not induce cytokines or expand iNKT cells (data
not shown).RGI-2001 Treatment Prolongs Mouse Survival
in an Acute GVHD Model
The efficacy of RGI-2001 in attenuating the
course of acute GVHD was evaluated using a murine
lethal GVHD model with complete MHC-
mismatched BMT (C57BL/6 /Balb/c). Varying
doses (0.001, 0.01, 0.1, 1, 10, and 100 mg/kg) of
RGI-2001 or the liposomal control containing a lipid
dose equivalent to that of 10 mg/kg of RGI-2001 were
administered i.v. immediately after TCD BMC 1
WSC transfusion, and survival was followed over 100
days. Efficacy was evaluated in at least two experiments
for each dose, and the combined results of two re-
presentative experiments are shown in Figure 1. Typ-
ically, untreated mice died by day 40-50 in this model.
The survival curve of mice that received the liposomal
control was similar to that of untreated mice
(Figure 1A). Statistically significant prolonged survival
was seen in mice that received RGI-2001 at doses$0.1
mg/kg, and 30%-60% of mice in these treatment
groups survived for .100 days (Figure 1A and B). Al-
though RGI-2001 treatment significantly prolonged
survival and reduced GVHD mortality, the mice de-
veloped substantial clinical manifestations of acute
GVHD, including weight loss, hunched posture, diar-
rhea, and ruffled fur. Clinical appearance improved in
survivors, and long-term (.100 days) survivors were
nearly free of symptoms. Although amodest but signif-
icant increase in survival was observed at a dose of 0.01
mg/kg (P 5 .0369), no mice survived for .100 days in
this group (Figure 1B). No significant effect was noted
in the mice that received 0.001 mg/kg of RGI-2001
(data not shown). Collectively, the efficacious dose of
RGI-2001 was determined to be $0.1 mg/kg. Survival
curves at doses of 0.1, 1, 10, and 100 mg/kg were com-
parable overall, and no trend toward dose-related dif-
ferences was noted within the effective dose range.
Thus, 1 mg/kg was selected as the standard dose used
in the rest of this study, unless specified otherwise.
Figure 1. Effects of RGI-2001 treatment on acute GVHD mortality. A
and B, Effects of varying doses of RGI-2001 and the liposomal control on
the survival of lethally irradiated Balb/c mice reconstituted with 5 106
TCD BMCs and 2.5 106WSCs of C57BL/6 (C57BL/6/Balb/c). RGI-
2001 was administered i.v. 30 minutes after the infusion of TCD BMCs
and WSCs. The liposome control contained a lipid dose equivalent to
10 mg/kg of RGI-2001. For each dose, results of two representative ex-
periments were combined. P values were calculated versus untreated
controls. C, The impact of treatment schedule on efficacy. Results of
a representative experiment from 4 experiments are shown. Survival
was compared in mice receiving RGI-2001 (1 mg/kg i.v.) on day 0, day
-3, day 2, or day 7 and untreatedmice (n5 5 for each group). The highest
efficacy was achieved by RGI-2001 administered on day 0, whereas effi-
cacy was abrogated with delayed administration (day 2 or day 7).
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by administering RGI-2001 (1 mg/kg) before (day -3),
concurrent with (day 0) or after (day 2 or day 7) BMT.
Representative results are shown in Figure 1C. Robust
efficacy was reproducibly observed in mice treated
on day 0, modest efficacy was seen in mice treated on
day -3, and no efficacy was seen in mice treated on
day 2 or day 7. These results were reproduced in 4
independent experiments. It was concluded thatadministration on day 0 (at the time of BMT) was
the most effective treatment schedule.
The levels of various serum proteins were investi-
gated on day 6 post-BMT (Table 1). Statistically sig-
nificant decreases were noted in the levels of IFN-g
and tumor necrosis factor-a in mice treated with
RGI-2001 (1 mg/kg) compared with untreated mice.
In addition, levels of acute-phase proteins (C-reactive
protein and haptoglobin) and chemokines (IP-10,
macrophage inflammatory protein [MIP]-1b, and
MIP-1g) were significantly reduced in RGI-2001–
treated mice, suggesting decreased severity of inflam-
mation and leukocyte trafficking in these mice. No
differences were noted in the levels of other cytokines,
including IL-6 and IL-10. IL-2, IL-12p70, and IL-17
were below detection levels in both groups.RGI-2001 Promotes Expansion of the
Donor-Derived Treg Compartment
Early after BMT
We hypothesized that RGI-2001 treatment might
reduce the severity of GVHD by inducing transplanta-
tion tolerance through the induction of Tregs, and
thus investigated Treg recovery after BMT. On day
15 post-BMT, cells from spleen; mesenteric lymph no-
des (mLNs); peripheral lymph nodes (pLNs), includ-
ing inguinal and axillary nodes; bone marrow (BM);
and peripheral blood (PB) were analyzed for CD41
Foxp31Tregs. First, it was confirmed that all cells (in-
cluding CD41 cells) in these organs were reconstituted
with H2-Kb1 donor-derived cells in both RGI-2001–
treated and untreated mice (Figure 2A, upper panels).
Staining for Foxp3 revealed marked increases in
Foxp31 cells within the CD41 cell population in
RGI-2001–treated mice compared with untreated
mice (Figure 2A, bottom panels). Higher percentages
of CD41Foxp31 Tregs were consistently found in
the tissues examined. This finding was highly repro-
ducible and confirmed to be significant in 4 indepen-
dent experiments. Combined data (Figure 2B, left)
demonstrated that 3- to 5-fold increases in the per-
centage of CD41Foxp31 cells were induced systemi-
cally by RGI-2001 treatment by day 15 post-BMT.
Differences were statistically highly significant in
all organs investigated. The absolute number of
CD41Foxp31 Tregs calculated in the spleen samples
was 0.8 6 0.5  105 cells in untreated mice (n 5 5)
and 7.5 6 1.3  105 cells in RGI-2001–treated mice
(n5 5). The10-fold increase in the number of Tregs
found in treated mice is highly statistically significant
(P\.0001). Higher percentages of Tregs were main-
tained in RGI-2001–treated mice compared with un-
treated mice on day 30 post-BMT (Figure 2B, right);
however, a highly statistically significant difference
(P\.005) was found only in the spleen. The percent-
age of Tregs in mLNs and pLNs in RGI-2001–treated
Table 1. Serum Protein Levels on Day 6 Post-BMT
IFN-g, pg/mL TNF-a, pg/mL CRP, mg/mL Haptoglobin, mg/mL IP-10, pg/mL MIP-1b, pg/mL MIP-1g, ng/mL
Untreated 395 ± 66 207 ± 17 3.96 ± 0.39 253 ± 27 3158 ± 271 1545 ± 177 109 ± 4
RGI-2001 181 ± 86* 149 ± 29* 2.81 ± 0.25** 79 ± 45** 1448 ± 341** 784 ± 147** 87 ± 12*
CRP indicates C-reactive protein; TNF, tumor necrosis factor.
Sera from untreated and RGI-2001–treated (1 mg/kg) mice (n5 4 for each group) were collected on day 6 post-BMTand analyzed using RodentMAP v 2.0
(Rules-Based Medicine, Austin, TX).
*P <.05.
**P <.005 versus untreated mice.
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15 post-BMT. In addition, as the earlier time point,
Tregs in the spleen were investigated on day 6 post-
BMT. The percentage of CD41Foxp31 Tregs was
1.7% 6 0.5% in untreated mice (n 5 4) and 5.6% 6
1.5% in RGI-2001–treatedmice (n5 4). The increases
were highly statistically significant compared with un-
treatedmice (P5 .0026), although the level of Tregs in
the treated mice was lower than that measured on day
15 (14.8% 6 7.6%). Taken together, these results
demonstrate that RGI-2001 treatment induced expan-
sion of Tregs early after BMT, during the GVHD ini-
tiation period, and that Tregs reached their highest
level in the secondary lymphoid organs around day 15.
Host Alloantigen-Specific Immune Suppression
Is Induced in RGI-2001–Treated Mice by Day 15
Post-BMT
The immunologic status of RGI-2001–treated
mice was analyzed by an in vitro mixed lymphocyte
reaction (MLR) assay. WSCs from RGI-2001–treated
(1 mg/kg) and untreated Balb/c mice reconstituted with
C57BL/6 BMC were harvested on day 15 post-BMT
and then cocultured with MMCMitomycin C-treated
TCD stimulator cells derived from Balb/c (host) or
C3H (third party) mice (Figure 2C). Marked suppres-
sion in response to Balb/c stimulators was observed in
cultures with cells from RGI-2001–treated mice com-
pared with those with cells from untreated controls. In
contrast, no suppression was observed in responses
against the third-party strain C3H. The percentage
of CD41Foxp31 Tregs in the spleen cells was 2.57%
6 0.82% in the untreated mice (n 5 5) and 18.8% 6
5.2% in the RGI-2001–treated mice (n 5 5). This
finding suggests that Tregs generated in RGI-2001–
treated mice may be responsible for the host-specific
MLR suppression, and that these Tregs may be
functional and enriched for those Tregs reactive to
host alloantigens.
RGI-2001 Induces Treg Expansion
in a Dose-Dependent Manner
We investigated the effects of varying doses of
RGI-2001, ranging from 0.001 to 100 mg/kg, on the
induction of Tregs. Mice were analyzed on day 15
post-BMT (Figure 3). The combined results of 6 ex-periments demonstrated clear dose-dependent in-
creases in the percentage of CD41Foxp31 cells in
both spleen (Figure 3A) and mLNs (Figure 3B). The
Treg levels in pLNs were significantly increased even
at the lowest dose evaluated (Figure 3C). The total
Treg cell counts in the spleen also increased in a
dose-dependent manner (Figure 3D), with 13.1 6
8.7  105 Tregs in mice treated with 100 mg/kg
RGI-2001 compared with 0.36 0.2 105Tregs in un-
treated mice. Overall, statistically significant Treg in-
duction was evident at doses $0.01 mg/kg. Our
findings indicate that RGI-2001 promotes expansion
of the donor-derived Tregs early after BMT in a
dose-dependent manner.
Efficacy Is Reproduced in a GVHD Model with
a Different MHC Combination
To confirm that the observed effects of RGI-2001
were not specific to the strains used in the foregoing
experiments, efficacy was evaluated in a model in-
volving a different strain combination, FVB (H2q)/
Balb/c (H2-Kd). RGI-2001 (1 mg/kg) significantly
prolonged the survival of these mice (P 5 .029)
(Figure 4A). T cell depletion in donor BMCs was not
performed in this experiment, due to the Thy1-1 hap-
lotype of FVB, which might explain the better out-
come of untreated mice, with 60% survival at .100
days. Nevertheless, the results confirm that RGI-
2001 treatment significantly improved survival of
mice in a GVHD model involving a different MHC
combination. The induction of Tregs by RGI-2001
was also confirmed in this model. On day 15 post-
BMT, a higher percentage of CD41Foxp31 cells was
detected in all organs in RGI-2001–treated mice (1
mg/kg), with statistically significant increases in spleen,
pLNs, and PB (Figure 4B). The absolute Treg count in
the spleen was 2.5-fold higher in the RGI-2001–
treated group than in the untreated group, a statisti-
cally significant difference (P 5 .0301).
RGI-2001 Induces Expansion of Naturally
Occurring Tregs
The origin of the Tregs induced by RGI-2001 was
investigated using Foxp3:GFP reporter mice [17]
(C57BL/6 background) as donors. Foxp3:GFP1 pre-
existing naturally occurring Tregs (nTregs) were
Figure 2. Early expansion of donor-derived CD41Foxp31 Tregs and induction of host alloantigen-specific immune suppression by RGI-2001. A and B,
Recovery of CD41Foxp31 Tregs was investigated in untreated and RGI-2001–treated (1 mg/kg, day 0) mice. A, Representative dot plots of spleen cells
analyzed on day 15 post-BMT. Upper panels: All CD41 cells were confirmed to be H2-Kb1 donor-derived cells. Numbers indicate the percentage of
CD41 cells in total spleen cells. Lower panels: Foxp3 expression in gated CD41 cells. Numbers in the upper-right quadrant indicate the percentages of
CD41Foxp31Tregs in total CD41T cells. B, Mean6 standard deviation (SD) percentages of CD41Foxp31 cells in total CD41 cells in the spleen, mLNs,
pLNs, BM, and PB analyzed on day 15 (left) and day 30 (right) post-BMT. The data combine results from 4 independent experiments; numbers in paren-
theses indicate the number of animals analyzed. P values versus untreated mice: *P\.05; ‡P\.005. C, Spleen cells from Balb/c mice reconstituted with
C57BL/6 TCD-BMC andWSC were harvested on day 15 post-BMTand subjected to MLR coculture stimulated with either MMCMitomycin C-treated
TCDBalb/c (host) or C3H (third party) spleen cells. The cultures were evaluated in triplicate. Mean6 SD values in mice treated with RGI-2001 (1 mg/kg)
(n5 5) and in untreated mice (n5 5) are shown. The percentage of CD41Foxp31 Tregs in the spleen cells in this experiment was 2.57%6 0.82% in the
untreated mice and 18.8% 6 5.2% in the RGI-2001–treated mice. P value is versus untreated.
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Figure 3. Dose-dependent induction of Tregs by RGI-2001 treatment. A, B, and C, Mean6 SD percentages of CD41Foxp31 cells in total CD41 cells in
the spleen (A), mLNs (B), and pLNs (C) analyzed on day 15 post-BMT. (D), Mean6 SD absolute number of CD41Foxp31 cells in the spleen analyzed on
day 15 post-BMT. Mice received RGI-2001 doses of 0.001-100 mg/kg on day 0. Data are the combined results from 6 independent experiments; numbers
in parentheses indicate the number of animals analyzed. P values for treated versus untreated: *P\.05; ‡P\.005.
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fusion into Balb/c recipients (Figure 5A). In the initial
experiment, the effect of RGI-2001 (1 mg/kg) was in-
vestigated in mice that received TCD BMCs and
Foxp3:GFP1-depleted spleen cells (2.5  106 cells).
In this group, 80% of the mice died by day 15. The
mice that received unsorted WSCs (2.5  106 cells)
or Foxp3:GFP1-depleted spleen cells (2.5  106 cells)
along withWSCs (1.25 106 cells) derived from wild-
typeC57BL/6mice (WTWSCs) survived (Figure 5B).
This finding indicates that nTregs present in the trans-
fused donor spleen cells were required for the control
of GVHD by RGI-2001. Thus, to supplement the
nTregs, WT WSCs (1.25  106 cells) were added to
Foxp3:GFP1-depleted spleen cells (2.5  106 cells)
in subsequent experiments. On day 15 post-BMT,
the percentage of CD41 Foxp3:GFP1 cells was inves-
tigated (Figure 5C and 5D). Inmice that received 2.5
106 of unsortedWSCs, RGI-2001 treatment (1 mg/kg)
gave rise to 9.0%6 3.4%CD41 Foxp3:GFP1 cells, an
approximate 5-fold increase over the level seen in un-
treated mice (1.8%6 1.0%). This level of increase was
comparable to that observed with C57BL/6 wild-type
WSCs, indicating comparable responsiveness ofFoxp3:GFP reporter mice. In contrast, the mice that
received an equivalent number of spleen cells that
were depleted for Foxp3:GFP1 preexisting nTregs to-
gether with 1.25  106 WT WSCs gave rise to only
1.6% 6 0.4% CD41 Foxp3:GFP1 cells after RGI-
2001 treatment, not significantly different from the
level in the untreated mice (1.1% 6 0.9%). These re-
sults indicate that the increase in Tregs induced by
RGI-2001 was due primarily to the expansion of pre-
existing Foxp3:GFP1 nTregs in the transfused
WSCs, with little contribution from inducible Tregs
(iTregs) converted from Foxp3:GFP- CD41 cells.Combination with a Subtherapeutic Dose
of RAPA Further Improves Efficacy
RAPA has been reported to have favorable effects
on Tregs [22,23]. Moreover, low-dose RAPA was
found to enhance the efficacy of a Treg-inducing his-
tone deacetylase (HDAC) inhibitor in cardiac and islet
cell transplantation models [24]. Consequently, the
efficacy of RGI-2001 in combination with low-dose
RAPA was evaluated. The subtherapeutic low dose of
RAPA was set at 0.1 mg/kg, which is lower than the
Figure 4. Efficacy of RGI-2001 in a different strain combination (FVB
/ Balb/c). A, Effects of RGI-2001 (1 mg/kg, day 0) on survival of lethally
irradiated Balb/c mice reconstituted with 5  106 BMCs and 2.5  106
WSCs of FVB were investigated. P values versus untreated. B, Mean 6
SD percentages of CD41Foxp31 cells in total CD41 cells in spleen,
mLNs, pLNs, BM, and PB analyzed on day 15 post-BMT in Balb/c mice
reconstituted with BMCs1WSCs derived from FVB. The results of un-
treated (n 5 3) and RGI-200–treated (n 5 4) mice are shown. P values
for treated versus untreated: *P\.05.
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kg) [25,26]. It was confirmed that daily injections of
RAPA at doses \0.5 mg/kg did not suppress the
induction of cytokines or the iNKT cell expansion
induced by RGI-2001 (1 mg/kg) in normal C57BL/6
mice (data not shown). In the GVHDmodel, the addi-
tion of low-dose RAPA to RGI-2001 reproducibly im-
proved survival compared with either single treatment
in two independent experiments (Figure 6A). The ma-
jority of mice that received the combination treatment
(RGI-2001 1 mg/kg on day 0 and RAPA 0.1 mg/kg
daily on days 0-14) survived for.100 days, with a sta-
tistically significant improvement over either single
treatment. Clinical scores and body weights also dem-
onstrated the greater efficacy of combination treat-
ment in reducing the severity of acute GVHD (data
not shown).
Treg levels on day 15 post-BMT were compared
in the treatment groups. RGI-2001 alone and
RAPA alone induced increases in the percentage of
CD41Foxp31 cells over untreated controls in spleen
(Figure 6B), mLNs (Figure 6C), and pLNs
(Figure 6D). The combination of RGI-2001 and
RAPA further increased Tregs to a significantly higher
level in all organs compared with either single treat-ment. This finding was reproduced in 3 independent
experiments. The absolute yields of Tregs were
increased as well. In 3 experiments, the total Treg
cell yield in mice that received the combination treat-
ment was 1.7- to 3.1-fold higher than that in mice
treated with RGI-2001 alone and 8.9- to 9.7-fold
higher than that in those treated with RAPA alone.
These increases in absolute Treg counts implied that
combination treatment induced further expansion of
the Treg compartment, excluding the possibility
that the increased percentage of Tregs might be
due to the relative enrichment of Tregs caused by
RAPA-induced suppression of the conventional
T cell compartment.
The effect of RAPA on Tregs was investigated us-
ing the Foxp3:GFP reporter mice (Figure 6E). In mice
receiving unsorted WSCs from Foxp3:GFP mice,
RAPA induced significant increases in the percentage
of Tregs (8.5% 6 2.6%). The combination of RGI-
2001 and RAPA further increased this percentage to
17.0% 6 3.6%. In contrast, in mice that received
spleen cells depleted for Foxp3:GFP1 nTregs together
with WT WSCs, the levels of Foxp3:GFP1 cells re-
mained low after RAPA or RGI-2001 1 RAPA treat-
ment, indicating that the expansion of preexisting
nTregs contributed to the majority of Tregs induced
by RAPA or RGI-20011 RAPA. Nonetheless, a trend
(albeit marginal) toward increased Foxp3:GFP1Tregs
in the mice treated with a RAPA-containing regimen
was seen. In contrast to RGI-2001 single treatment
(Figure 5C), the differences appeared to be statistically
meaningful, suggesting the possibility that RAPA
might promote the de novo conversion of na€ıve T cells
to iTregs.RGI-2001 Treatment Does Not Abrogate
Graft-versus-Leukemia Activity
The influence of RGI-2001 on graft-versus-
leukemia (GVL) activity was investigated using a
well-established GVL model involving Balb/c-
derived, YFP/luciferase-expressing A20 leukemia cells
[19]. First, it was confirmed that RGI-2001 treatment
did not affect the growth of A20-luc/yfp cells in vivo. In
lethally irradiated Balb/c mice undergoing transplan-
tation with syngeneic BMC and A20-luc/yfp cells, a
distinct population of B220hi/YFP-Luc1 leukemia
cells was noted in the spleen on day 26 (Figure 7A).
The levels of leukemia cell growth were comparable
in both RGI-2001–treated and untreated mice. The
growth of leukemia cells was then investigated in
mice reconstituted with allogeneic C57BL/6 TCD
BMCs. In mice undergoing transplantation with
C57BL/6 TCD BMCs without WSCs, growth of leu-
kemia cells was macroscopically evident in the liver
and spleen. FACS analysis of cells from spleen and
BM on day 32 revealed the B220hi/YFP-Luc1
Figure 5. Expansion of donor-derived GFP1 nTregs by RGI-2001 treatment. The origin of CD41Foxp31 cells induced by RGI-2001 after BMTwas
investigated using Foxp3:GFP reporter mice as donors. A, Representative dot plots showing WSCs and sorted Foxp3:GFP1-depleted spleen cells.
The cell sorting strategy routinely yielded.99% purity in Foxp3:GFP1-depleted spleen cells. B, Survival of Balb/c recipients that received various spleen
cell preparations: 2.5 106WSCs containing Foxp3:GFP1 nTregs (WSC), 2.5 106 spleen cells depleted of Foxp3:GFP1 nTregs (Foxp3:GFP1-depl), or
2.5  106 spleen cells depleted of Foxp3:GFP1 nTregs and 1.25  106 wild-type C57BL/6 WSCs (Foxp3:GFP1-depl 1WT WSC). Mice were treated
with RGI-2001 (1 mg/kg, day 0). By day 15, 80% of the mice that had received Foxp3:GFP1-depl died. The P value for Foxp3:GFP1-depl versusWSC was
0.0564 (log-rank test). The mice that receivedWSC (n5 5), Foxp3:GFP1-depl (n5 5), or Foxp3:GFP1-depl1WTWSC (n5 4), but not RGI-2001, all
survived until day 15. C and D, Recovery of CD41Foxp3:GFP1 Tregs in untreated and RGI-2001–treated mice was investigated on day 15 post-BMT. C,
Representative dot plots showing GFP1 cells in CD41 T cells in mice that receivedWSC or Foxp3:GFP1-depl1WTWSC, with or without RGI-2001
treatment. D, Mean 6 SD percentages of CD41Foxp3:GFP1 cells in total CD41 cells. Data are combined results from 4 independent experiments;
numbers in parentheses indicate the number of animals analyzed. P values versus untreated. InjectedWSCs contained on average 6.0 104 Foxp3:GFP1
cells. On day 15, 68.2 6 27.3  104 Foxp3:GFP1 cells were recovered from the spleens in the treated group (n 5 8), indicating a robust expansion
(11.4-fold) of Foxp3:GFP1 nTregs. The spleens in the untreated group contained 4.2 6 2.4  104 Foxp3:GFP1 cells (n 5 8).
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kemia cells were detected in the mice that received
C57BL/6 WSCs 1 A20-luc/yfp with or without RGI-
2001 (Figure 7B). An experiment following survival
showed that the mice that did not receive the WSCs
did not develop GVHD symptoms but began dying
on day 24, and all died of leukemia by day 39
(Figure 7C). The mice that received only WSCs all
died by day 39 due to acute GVHD. The mice receiv-
ing WSCs 1 A20-luc/yfp developed clinical signs of
GVHD. The survival curve of this group was very sim-
ilar to that of the WSC-only group, indicating acute
GVHD as the cause of death in this group. In contrast,
the mice receiving WSCs 1 A20-luc/yfp 1 RGI-2001
survived longer, although they also developed clinical
GVHD. In this group, 50% of the mice died of
GVHD, but the remaining 50% recovered fromGVHD and survived up to termination of the experi-
ment on day 68, which was in the range anticipated
for the mice treated with RGI-2001, as noted earlier
(1 mg/kg; Figure 1B). At study termination on day
68, no YFP-Luc1 leukemia cells were detected in these
mice. Similar survival results were reproducibly ob-
served in 3 independent experiments.
The levels of CD41Foxp31 cells in mice that
received A20-luc/yfp cells were then analyzed on day
15 post-BMT. The mice receiving WSCs 1 A20-luc/
yfp 1 RGI-2001 (n 5 4) had 19.3% 6 6.5% CD41
Foxp31 cells in the spleen, a level comparable to that
seen in historical controls receiving WSCs 1 RGI-
2001 (14.8% 6 7.6%; Figure 2B). These results
indicate that the presence of leukemia cells did not in-
fluence the Treg expansion by RGI-2001, and that
Tregs induced by RGI-2001 in the presence of
Figure 6. Enhanced efficacy and Treg induction by RGI-2001 in combination with a subtherapeutic dose of RAPA. Effects of combination treatment with
RGI-2001 (1 mg/kg, day 0) and a subtherapeutic dose of RAPA (0.1 mg/kg i.p. daily on days 0-14) on survival and Treg induction were evaluated. A, Survival
curves of mice that received RGI-2001 alone, RAPA alone, or RGI-20011 RAPA. Results of two experiments were combined. P values comparing either
RGI-2001 or RAPA single-treatment group versus RGI-2001 1 RAPA treatment group. B, C, and D, Mean 6 SD percentage of CD41Foxp31 cells in
total CD41 cells in the spleen (B), mLNs (C), and pLNs (D) analyzed on day 15 post-BMT. Results are from 3 independent experiments; numbers in
parentheses indicate the number of animals analyzed. Historical untreated control data are included as a reference. P values comparing either RGI-
2001 or RAPA single treatment group versus RGI-2001 1 RAPA treatment group. E, The origin of CD41Foxp31 cells induced by the RAPA-
containing regimen was investigated using Foxp3:GFP reporter mice as donors. Mice received WSCs or Foxp3:GFP1-depleted spleen cells and WT
WSCs, as described in Figure 5, and were treated with RAPA or RGI-2001 1 RAPA or were untreated. The mean 6 SD percentage of
CD41Foxp3:GFP1 cells in total CD41 cells in the spleen analyzed on day 15 post-BMT is shown. Data are combined results from 4 independent ex-
periments; numbers in parentheses indicate the number of animals analyzed. P values are versus untreated.
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Figure 7. Effects of RGI-2001 on GVL activity were investigated using a GVL model involving Balb/c-derived, YFP/luciferase-expressing A20 leukemia
cells (A20-luc/yfp). A, Growth of A20-luc/yfp in a syngeneic BMT model with and without RGI-2001 treatment. Lethally irradiated Balb/c mice received
syngeneic BMCs (5  106) and A20-luc/yfp (5  104) cells with or without RGI-2001 treatment (1 mg/kg, day 0) and were analyzed for leukemia cell
growth on day 26 (n 5 3 for each group). Representative FACS plots of the spleen illustrate a distinct population of B220hi/YFP-Luc1 leukemia cells
in both untreated and RGI-2001–treated mice. RGI-2001 did not suppress the growth of A20-luc/yfp. B, Growth of A20-luc/yfp in a GVHD model
with and without RGI-2001 treatment. Lethally irradiated Balb/c mice received C57BL/6 TCD BMCs (5  106) along with A20-luc/yfp (5  104),
C57BL/6 WSCs (2.5  106)1 A20-luc/yfp (5  104), or C57BL/6 WSCs (2.5  106)1 A20-luc/yfp (5  104)1 RGI-2001 (1 mg/kg) and were analyzed
on day 32 (n 5 3 for each group). Representative FACS plots of the BM demonstrate the growth of the B220hi/YFP-Luc1 leukemia cells in mice that
received A20-luc/yfp without C57BL/6 WSCs. No leukemia cells were detected in mice that received C57BL/6 WSCs 1 A20-luc/yfp with or without
RGI-2001. C, Survival of mice that received A20-luc/yfp. Lethally irradiated Balb/c mice received C57BL/6 TCD BMCs along with A20-luc/yfp,
C57BL/6 WSCs, C57BL/6 WSCs1 A20-luc/yfp, or C57BL/6 WSCs1 A20-luc/yfp1 RGI-2001, with the same protocol as in B. Results of a represen-
tative experiment out of 4 experiments are shown.
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cells. Taken together, these results demonstrate that
RGI-2001 suppressed acute GVHD without compro-
mising the GVL effect.DISCUSSION
Our results indicate that a liposomal formulation
of KRN7000 (RGI-2001) can prevent acute GVHD
by expanding Tregs in vivo. In a fully MHC-
mismatched acute GVHD murine model, a single i.v.
injection of RGI-2001 at the time of BMT demon-
strated significant efficacy in prolonging the survival
of mice that were otherwise acutely fatal. In mice
treated with RGI-2001, host alloantigen-specific tol-
erance was introduced early after BMT. The immune
response against third-party alloantigens and leukemia
cells was not compromised. RGI-2001 treatment in-
duced significant increases in donor-derived
CD41Foxp31 nTregs in the secondary lymphoid or-
gans including spleen, mLNs, and pLNs. The increase
in nTregs was noted in the spleen as early as day 6
post-BMT. The survival of mice that received
nTreg-depleted donor cells was not improved by
RGI-2001 treatment. Based on these findings, effec-
tive Treg induction by RGI-2001 can be considered
the key mechanism of action underlying the reduced
mortality and prolonged survival in the RGI-2001–
treated mice.
Collectively, our results demonstrate the efficacy
of pharmacologically induced nTregs in preventing
acute GVHD without abrogating the GVL effect.
The finding is in line with the pivotal role of donor-
derived Tregs in controlling GVHD reported in
both experimental and clinical studies [27-32]. In
mice, adoptive transfer of donor-derived
CD41CD251 Tregs was shown to inhibit GVHD
while maintaining GVL [29-30]. Likewise, it was
recently reported that adoptive immunotherapy with
donor-derived CD41CD251 Tregs prevented
GVHD in patients who received haploidentical trans-
plants for the treatment of high-risk hematologic ma-
lignancies [33]. Our findings indicate the efficacy of
Tregs pharmacologically induced in vivo, corroborat-
ing the earlier findings generated using the adoptive
transfer of Tregs.
RGI-2001 treatment significantly enhanced the
expansion of donor-derived CD41Foxp31Tregs early
after BMT.Using the Foxp3:GFP reporter mice as do-
nors, we clearly showed that these Tregs were derived
from existing nTregs within the transfused donor
spleen cells. It is conceivable that RGI-2001 promoted
the rapid expansion of nTregs with pre-endowed anti-
gen specificity to host antigens in an allogeneic host
environment. The marked suppression seen in MLRs
stimulated with host cells indicates that the expandednTregs were functional and facilitated host
alloantigen-specific immune suppression. Our results
are in accordance with those of a previous study that
directly compared the efficacy of GVHD prevention
of nTregs and iTregs using Foxp3:GFP reporter
mice [34,35]. Koenecke et al. [34] reported that adap-
tively transferred FACS-sorted nTregs significantly
improved survival andmorbidity, whereas iTregs, con-
verted from Foxp3:GFP- CD4 T cells in vitro, rapidly
lost the Treg features and failed to prevent GVHD. In
contrast, another study found that iTregs converted
from effector T cells in vivo by the hypomethylating
agent azacitidine mitigated GVHD while preserving
the GVL effect [36]. In that study, however, the sup-
pressor function of these cells was mediated through
the modulation of Foxp3 target genes by azacitidine,
independent of Foxp3 expression [36].
In the present study, significant increases in Tregs
in mLNs and pLNs were noted early (by day 15) after
BMT, and significant increases in Tregs in the spleen
were observed as early as day 6 post-BMT. Further-
more, delayed treatment with RGI-2001 resulted in
a loss of efficacy, reinforcing the importance of early
activity of Tregs in GVHD prevention at the site of
GVHD initiation. Secondary lymphoid organs, partic-
ularly lymph nodes proximal to GVHD target organs,
are considered the sites for GVHD induction [37,38].
Thus, Tregs may efficiently execute their suppressive
activity in these sites, where host antigen-presenting
cells actively stimulate donor-derived alloreactive
T cells. A study using whole-body bioluminescence
imaging elegantly demonstrated that adoptively trans-
ferred Tregs initially localize and expand in the sec-
ondary lymphoid organs, such as mLNs, pLNs, and
spleen [32]. Other studies found that adoptively trans-
ferred Tregs, particularly those expressing homing
molecules to the secondary lymphoid organs, such as
CD62L (L-selectin), ameliorate GVHD by interfering
with the activation, expansion, and migration of
GVHD effector T cells in these sites [39,40]. Those
studies demonstrated that Treg activity early after
BMT (before the onset of the effector phase) is
essential for GVHD prevention [32,39]. Taken
together, these previous findings and our present
results indicate that spatially and temporally
coordinated Treg activity is the key for effective
prevention of GVHD. Of note, Treg levels in mLNs
and pLNs decreased by day 30 post-BMT. Investigat-
ing whether RGI-2001 treatment leads to increased
Treg levels in GVHD target organs, such as the gut
and liver, by this time point would be of interest.
The action of RGI-2001 is initiated through the
interaction of KRN7000 and iNKT cells. The role of
NKT cells in GVHD prevention has been demon-
strated through the establishment of nonmyeloablative
total lymphoid irradiation (TLI) conditioning of the
host [41-45]. Fractionated irradiation of the lymphoid
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the host lymphoid organs, due primarily to the more
profound depletion of non-NKT cell populations
[41]. Mice conditioned with a TLI regimen are pro-
tected from GVHD, which is lethal for hosts condi-
tioned with total body irradiation. GVHD protection
by TLI conditioning is lost when donor CD41CD251
Tregs are depleted before transplantation [43], and
host NKT- and IL-4–dependent expansion of donor-
derived Tregs provides a mechanism to regulate
GVHD in this regimen [45]. Thus, GVHD protection
afforded by RGI-2001 and TLI conditioning might
possibly share a common underlying mechanism.
Both host- and donor-derivedNKT cells have been re-
ported to prevent GVHD [46]. Future studies using
NKT-lacking knockout mice, such as CD1d2/2 and
Ja182/2mice,will help identify theorigin ofNKTcells
involved in GVHD suppression by RGI-2001. Al-
though the mechanisms downstream of NKT cells
leading to Treg induction are not clearly understood,
we recently found that RGI-2001 preferentially in-
duces the expansion of tolerogenic plasmacytoid DCs
that precedes Treg expansion (data not shown).
The results of our experiments using the
Foxp3:GFP reporter mice clearly demonstrate that
the majority of Tregs induced by RGI-2001 and/or
RAPA were derived from pre-existing nTregs. How-
ever, in the mice treated with a RAPA-containing
regimen, marginal but statistically meaningful in-
creases in Tregs were noted in those mice transfused
with Foxp3:GFP1-depleted spleen cells, suggesting
a minor contribution of de novo converted iTregs in-
duced by RAPA treatment. Accumulated evidence in
recent years indicates that RAPA exerts favorable
effects on Tregs [22,23]. RAPA has been reported
to preferentially inhibit the proliferation of
conventional T cells while sparing Tregs [26,47], to
induce selective expansion of murine [48] and human
[6,49] naturally occurring CD41CD251Foxp31
Tregs in vitro, and to induce Foxp3 expression
and regulatory functions in conventional CD41
T cells in vitro [49,50]. Our results indicate that
RAPA promotes expansion of nTregs and may also
promote, to a lesser extent, de novo induction of
iTregs in vivo in a lymphopenic allogeneic condition.
In the present study, the efficacy of RGI-2001 in
attenuating the course of acute GVHD was seen at
doses of 0.1-100 mg/kg. This dose range correlates
well with the biological activity measured by cytokine
induction ($0.01 mg/kg; Figure S1A-C) and Treg ex-
pansion ($0.01 mg/kg; Figure 3). Dose-related protec-
tion from GVHD lethality by RGI-2001 was observed
at doses of 0.001-0.1 mg/kg, with no efficacy at 0.001
mg/kg, limited efficacy at 0.01 mg/kg, and significant
efficacy at 0.1 mg/kg. However, within the effective
dose range (0.1-100 mg/kg), no clear dose-related
improvement in survival was noted (Figure 1A and B)despite the dose-dependent increases in Tregs
(Figure 3D). It is possible that the magnitude of in-
crease in Tregs within the effective dose range might
not be sufficient to translate into a robust improve-
ment in survival. The changes in the Treg:T conven-
tional T cell ratio, which is considered to affect the
efficacy of Tregs [28], was modest within the effective
dose range. The increase in the CD41Foxp31
Treg:CD41Foxp32 T conventional T cell ratio in
the spleenwas about 2-fold, from1:9 at 0.1mg/kg (min-
imum effective dose) to 1:4 at 100 mg/kg. Likewise, the
increase in absolute Treg numbers was 5-fold at the
100-mg/kg dose compared with the 0.1-mg/kg dose.
However, when combined with a subtherapeutic dose
of RAPA, survival improved significantly. Although
this survival improvement was associated with syner-
gistic increases in Tregs, additional effects of RAPA
on other cell types, such as suppression of effector cells,
might possibly be attributable to the improved efficacy.
Contradictory to our findings, a recent study found
that KRN7000 induced hyperacute GVHD inmice re-
constituted with hematopoietic stem cells derived
from the spleen of granulocyte-colony stimulating
factor–treated mice [51]. In the present study, no
acceleration ofGVHDwas observed at any of the doses
evaluated. Differences in the hematopoietic stem cell
source may explain the difference in outcomes; Kuns
et al. [51] reported a lower incidence of hyperacute
GVHD with the use of BMCs instead of spleen cells
from granulocyte-colony stimulating factor–treated
mice. Furthermore, no hyperacute GVHD was re-
ported in previous studies evaluating the effect of
KRN7000 inGVHDusingBMCs [52]. Further studies
are needed to identify the precise mechanisms involved
in these contradictory effects.
A promising result reported from a recent clinical
study evaluating the efficacy in GVHD prevention of
adoptive immunotherapy with freshly isolated donor-
derived Tregs [33] corroborates the pivotal role of
Tregs in GVHD control in humans. Considering the
lack of efficacy of in vitro expanded Tregs, either
iTregs [34,35], or nTregs [53], along with the paucity
of therapeutic nTregs in PB, drugs that can pharmaco-
logically induce nTregs in vivo would provide a signif-
icant benefit. Several compounds in addition to
RGI-2001 have been reported to induce Tregs in
vivo through different mechanisms. The HDAC in-
hibitor trichostatin A increases Foxp3 gene expression
as well as the production and suppressive function of
Foxp3-dependent Tregs through inhibition of
HDAC9 [24]. An agonist of the aryl hydrocarbon re-
ceptor, VAF347, induces long-term active tolerance
to alloantigens through a direct effect on Treg survival
and function, as well as through DC-mediated induc-
tion of Tregs [54]. The hypomethylating agent
azacitidine reportedly converts effector T cells into
Foxp31 iTregs and induces suppressor function
Biol Blood Marrow Transplant 17:1154-1168, 2011 1167GVHD Prevention by In Vivo Expanded Tregsthrough epigenetic modulation of Foxp3 and its target
genes [36]. Induction and maintenance of antigen-
specific tolerance by compounds that exploit intrinsic
immunomodulatory mechanisms may provide signifi-
cant clinical benefits to patients undergoing allogeneic
hematopoietic stem cell transplantation, as well as
those undergoing solid organ transplantation.ACKNOWLEDGMENTS
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